Spevigo (spesolimab-sbzo)

Spevigo is a biologic approved for the treatment of generalized pustular psoriasis.

What is Spevigo?

Spevigo (also known by its generic name spesolimab-sbzo) was approved in 2022 for the treatment of adults with generalized pustular psoriasis (GPP) flares. In 2024, Spevigo was approved for the treatment of GPP in adults and pediatric patients aged 12 and above weighing ≥40 kg.

In adults experiencing GPP flares, Spevigo is administered once by intravenous (IV) infusion. If flare symptoms persist, a second dose may be administered one week after the initial dose.

In adults and pediatric patients aged 12 and above weighing ≥40 kg not experiencing a GPP flare, Spevigo is given by injection under the skin. The initial dose is given at week 0 (the first week of treatment) and then every 4 weeks afterward.

To learn more, please visit the Spevigo website.

A mother and father give their two daughters piggyback rides on the beach.

FDA Expands Approval of SPEVIGO® for Generalized Pustular Psoriasis

SPEVIGO® is now approved to treat GPP in adults and children aged 12 and above.

Read more
Elderly Asian woman and Black man embracing and smiling outside.

FDA Approves SPEVIGO® for Adults with GPP

The first FDA-approved treatment for generalized pustular psoriasis.

Learn more
A woman doctor holds a clipboard and explains something to a patient.

Get the Facts

Learn more about the different types of biologics for psoriatic disease, including risks and side effects.

Request your resources

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.